139 related articles for article (PubMed ID: 10500778)
1. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Veil A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Tilly H; Brice P; Lioure B; Desablens B; Pignon B; Abgrall JP; Leporrier M; Fenaux P
Adv Exp Med Biol; 1999; 457():35-46. PubMed ID: 10500778
[TBL] [Abstract][Full Text] [Related]
2. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Mahé B; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Buzyn A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Stamatoulas A; Tilly H; Brice P; Maloisel F; Lioure B; Desablens B; Fenaux P
Br J Haematol; 1998 Sep; 102(4):1015-24. PubMed ID: 9734653
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Wattel E; Solary E; Leleu X; Dreyfus F; Brion A; Jouet JP; Hoang-Ngoc L; Maloisel F; Guerci A; Rochant H; Gratecos N; Casassus P; Janvier M; Brice P; Lepelley P; Fenaux P
Leukemia; 1999 Apr; 13(4):524-9. PubMed ID: 10214857
[TBL] [Abstract][Full Text] [Related]
4. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
Lepelley P; Poulain S; Grardel N; Preudhomme C; Cosson A; Fenaux P
Leuk Lymphoma; 1998 May; 29(5-6):547-51. PubMed ID: 9643568
[TBL] [Abstract][Full Text] [Related]
5. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
Solary E; Witz B; Caillot D; Moreau P; Desablens B; Cahn JY; Sadoun A; Pignon B; Berthou C; Maloisel F; Guyotat D; Casassus P; Ifrah N; Lamy Y; Audhuy B; Colombat P; Harousseau JL
Blood; 1996 Aug; 88(4):1198-205. PubMed ID: 8695837
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Prébet T; Ducastelle S; Debotton S; Stamatoullas A; Deconinck E; Fruchart C; Gratecos N; Ifrah N; Dreyfus F; Fenaux P; Wattel E;
Hematol J; 2004; 5(3):209-15. PubMed ID: 15167906
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Greenberg PL; Lee SJ; Advani R; Tallman MS; Sikic BI; Letendre L; Dugan K; Lum B; Chin DL; Dewald G; Paietta E; Bennett JM; Rowe JM
J Clin Oncol; 2004 Mar; 22(6):1078-86. PubMed ID: 15020609
[TBL] [Abstract][Full Text] [Related]
9. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.
Solary E; Drenou B; Campos L; de Crémoux P; Mugneret F; Moreau P; Lioure B; Falkenrodt A; Witz B; Bernard M; Hunault-Berger M; Delain M; Fernandes J; Mounier C; Guilhot F; Garnache F; Berthou C; Kara-Slimane F; Harousseau JL;
Blood; 2003 Aug; 102(4):1202-10. PubMed ID: 12663440
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
Solary E; Caillot D; Chauffert B; Casasnovas RO; Dumas M; Maynadie M; Guy H
J Clin Oncol; 1992 Nov; 10(11):1730-6. PubMed ID: 1357108
[TBL] [Abstract][Full Text] [Related]
11. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
12. Eprenetapopt Plus Azacitidine in
Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
[TBL] [Abstract][Full Text] [Related]
13. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
15. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
19. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
20. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
